Ravi A. Madan, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 13N240B
- Bethesda, MD 20892
Dr. Madan's clinical research is focused on several aspects of prostate cancer including early recurrent disease, the potential role of immunotherapy in treating the disease and the emerging utility of PET imaging. These clinical trials span the natural history of prostate cancer from newly diagnosed patients, to early recurrent disease and advanced castration-resistant metastatic prostate cancer.
Dr. Madan is also the Program Director of CCR's Physician-Scientist Early Investigator Program.
Areas of Expertise
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
For patients with early recurrent disease defined by a rising PSA after surgery or radiation (often called biochemical recurrence) the focus of Dr. Madan's research program is to extend this potentially indolent phase with out suppressing systemic testosterone levels. Dr. Madan has explored multiple immune strategies, anti-androgen strategies without androgen deprivation, and radiopharmaceuticals in this setting. The emphasis of the trials in this setting is to delay the need for androgen suppression, while maintaining quality of life with treatments that are associated with minimal if any toxicity.
Dr. Madan is exploring the role of PET imaging in recurrent prostate cancer by defining the natural history of the disease in this setting. This approach will help better understand the need for therapy in patients with otherwise negative CT or Tc99 bone scan. Future trials will use AI (artificial intelligence) to better target areas of aggressive cancer within prostate cancer patients.
While immune checkpoint inhibitors are rarely effective in prostate cancer, Dr. Madan is investigating other immunotherapy strategies in the clinic. This includes the use of immunocytokines to impact the broader tumor immune microenvironment beyond just T-cells. The goal here is to deliver immunotherapy in a targeted manner that maximized immune impact while minimizing systemic toxicities. Dr. Madan has several trials ongoing in many stages of prostate cancer with immunocytokines.
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide
Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits
With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer
Ravi A. Madan, M.D.
Dr. Madan is a Senior Clinician at the National Cancer Institute (NCI), conducting clinical research in prostate cancer with a focus on immunotherapy strategies. Dr. Madan received his M.D. from the Rutgers-New Jersey Medical School in 2001 and completed his internal medicine residency at Rutgers-University Hospital in June 2004. He joined the NCI Medical Oncology Branch as an oncology/hematology fellow in 2005. In 2009 he was appointed to the position of Assistant Clinical Investigator. In 2014 he was made the Clinical Director of the Genitourinary Malignancies Branch and in 2018 he was appointed to the role of Senior Clinician. He holds a joint appointment in the Center for Immuno-Oncology which forms the basis for many of his clinical collaborations. His research interests are focused on immune stimulating therapeutic cancer vaccines and novel therapies in the treatment of prostate cancer.
Dr. Madan serves on many international review and research committees, including for organizations like the Veteran's Association and Prostate Cancer UK. He also currently serves as the Chair of the FDA's Oncologic Drugs Advisor Committee (ODAC).
We have no open positions in our group at this time, please check back later.
To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.